Get started
Author

Danielle Elsberry

Digitally guided microdissection aids somatic mutation detection in difficult to dissect tumors
2015 · Katherine Geiersbach, Nils Adey, et al. · Cancer Genetics · 26
Clinical validation of the Prosigna breast cancer prognostic gene signature assay on formalin-fixed paraffin embedded breast cancer tumors with comparison to standard molecular markers.
2014 · Roy R. L. Bastien, Cecily Vaughn, et al. · Journal of Clinical Oncology · 3
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al. · Blood Cancer Discovery · 1
PDF
Supplementary Figure 5 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Table 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Table 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Clinical Protocol 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Data from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Figure 1 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Figure 4 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Figure 6 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Figure 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Figure 3 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Supplementary Table 2 from Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
2026 · Sumithira Vasu, Nathan Denlinger, et al.
Optimization of a Clinically Validated Cart Flow Assay for Commercial Anti-cd19 Cart T-cell Therapy and Universal Assays for Detection of Novel Car-t Constructs
2024 · N. Denlinger, N. Doseck, et al. · Cytotherapy
Validation of Mycoplasma Stability in Snap-frozen Cultured Cells in Media to Enable Batching of Pcr Testing
2024 · D. Elsberry, T. Mead, et al. · Cytotherapy
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MALIGNANCIES
2023 · N. Denlinger, H. Bradbury, et al. · Cytotherapy
A Transgenic Zebrafish Model of Signaling Through Toll-Like Receptors
2014 · Elsberry, Danielle · J. Willard Marriott Library
Works count: 18
Citation count: 30
H-index: 2
I10-index: 1
Year
Topic
Type